Upgrade to SI Premium - Free Trial

Oppenheimer Maintains Outperform Rating and $76 PT on Sarepta Therapeutics (SRPT) Following In-line FY17 Sales Guidance Estimates

March 1, 2017 9:38 AM
Oppenheimer and Co. analyst Hartaj Singh reiterates Outperform rating and $76 price target on Sarepta Therapeutics (NASDAQ: SRPT), as the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles